Cempra completes patient enrollment of solitaire-IV phase 3 clinical trial
Cempra announced completion of enrollment for the global Solitaire-IV Phase 3 trial of solithromycin in adult patients with moderate to moderately severe community-acquired bacterial pneumonia. Top-line efficacy and safety data from this study are expected to be announced by the end of the year. July 07, 2015